Jacqueline Nelson
Family · Lovington, NMNPI 1255882718
Payments from drug & device makers
Across 201 payments — averaging $14.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$905
- AbbVie$473
- Lilly USA, LLC$285
- Novartis$196
- Amgen$184
- UCB, Inc.$109
- plus $776 from 16 others
What the payments were for
- Food & beverage$2,927100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 82 | $905 |
| AbbVie(2 entities) | 33 | $473 |
| Lilly USA, LLC | 11 | $285 |
| Novartis | 12 | $196 |
| Amgen | 15 | $184 |
| UCB, Inc. | 4 | $109 |
| Biogen | 6 | $108 |
| Jazz Pharmaceuticals Inc. | 6 | $103 |
| Upsher-smith Laboratories LLC | 6 | $99 |
| CSL Behring | 6 | $95 |
| Axsome Therapeutics, Inc. | 3 | $81 |
| Neurocrine Biosciences, Inc. | 3 | $61 |
| Harmony Biosciences LLC | 2 | $41 |
| Pfizer | 2 | $33 |
| Lundbeck LLC | 2 | $31 |
| Scilex Pharmaceuticals Inc. | 2 | $30 |
| SK Life Science, Inc. | 1 | $17 |
| Amneal Pharmaceuticals LLC | 1 | $16 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $16 |
| Grifols USA, LLC | 1 | $15 |
| Bristol Myers Squibb | 1 | $15 |
| EMD Serono, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,927 in reported general payments places this provider in the 90th percentile of 1,080 family providers in New Mexico.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 23 | $201,235 |
| Austedo XrDeutetrabenazine | 15 | $100,059 |
| QuliptaAtogepant | 12 | $31,252 |
| UbrelvyUbrogepant | 19 | $22,075 |
| Emgality SyringeGalcanezumab-Gnlm | 12 | $19,923 |
| Aimovig AutoinjectorErenumab-Aooe | 21 | $14,433 |
| Sumatriptan | 11 | $3,604 |
| Memantine Hcl | 89 | $1,602 |
| Donepezil Hcl | 118 | $1,303 |
| Aripiprazole | 21 | $1,102 |
| Sumatriptan Succinate | 31 | $1,082 |
| Teriflunomide | 14 | $663 |
| Nortriptyline Hcl | 42 | $616 |
| Topiramate | 44 | $471 |
| Gabapentin | 20 | $462 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $905 | $100,05915 claims |
| AbbVieQulipta, Ubrelvy | $473 | $53,32631 claims |
| Upsher-smith Laboratories LLCTopiramate | $99 | $47144 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,080 family providers in New Mexico.
Other family in Lovington
- Ocotlan MontoyaLovington$6K
- Victor NaikLovington$3K
- David SeiterFarmington$194K
- Carol HollandRoswell$81K
- Barbara FranklinAlbuquerque$28K
- Laurie CrockettArtesia$19K
- Kaylene CribbsFarmington$17K
- Melanie DuranAlbuquerque$15K
- Irasema LlewellynAlbuquerque$14K
- Jamie LujanLas Cruces$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.